Latest technology news and innovations
Every new parent grapples with a mix of emotions and decisions, often feeling overwhelmed. A pediatrician shares valuable insights from years of experience.
Bristol Myers Squibb receives FDA clearance for a novel myeloma treatment, while PBMs shift towards greater price transparency with TrumpRx comparisons.
Valisure is suing U.S. Pharmacopeia, alleging false claims about its drug testing methods and an attempt to undermine its reputation.
Bristol Myers Squibb's Zenbexus, a groundbreaking oral therapy for multiple myeloma, has gained FDA approval, marking a significant milestone in treatment options.
The CMS's recent ruling against funding pediatric gender-affirming treatment could face robust legal challenges, impacting future healthcare practices.
Commure has suspended payments under its referral program tied to AI products, just days before a critical investigation was published.
Splitting the MMR vaccine could lead to missed doses and increased illness among children, echoing past lessons from vaccine history.
FDA nixes a radiopharma drug by ITM Isotope Technologies, while Hims & Hers plans to enter the peptides market amidst evolving regulations.
Skylark Bio has initiated a clinical trial aimed at treating hearing loss in children with GJB2 mutations, following advancements in gene therapy.
Abortion care is evolving, with patients increasingly turning to digital solutions for reliable information and medical guidance.
MoonLake Immunotherapeutics faces scrutiny for vague disclosures on its autoimmune drug candidate, raising questions about its trial results’ credibility.
Nurses are increasingly spotlighting the risks of clinical AI, advocating for a collaborative approach to its development and deployment in healthcare.
Medicare's “Bridge” program aims to lower costs for GLP-1 medications, yet its complexity may hinder patient access to affordable treatments.
The FDA has rejected ITM-11 due to manufacturing concerns, hindering its potential as a competitor to Novartis’ treatment for rare neuroendocrine tumors.
The FDA now requires manufacturers to disclose food additive details, enhancing oversight for substances previously lacking regulation.
The recent Senate hearings on Covid-19's origins spotlight political distractions, while China's suppression of information remains a pivotal issue.
The NIH's proposed changes to funding eligibility may limit opportunities for international researchers on visas in the U.S. biomedical sector.
Replimune's new melanoma treatment gains FDA approval, while a Medicare policy change delays price negotiations for AbbVie drugs.
As Boston's biotech sector grapples with talent migration to California, new discoveries in Alzheimer's research signal both change and opportunity.
As AI tools proliferate in healthcare, the erosion of physician autonomy raises questions about clinical judgment, responsibility, and professional independence.